drug: sertindole
- Clinical class: atypical antipsychotic
- Action: serotonin-dopamine antagonist
- CSA schedule: none
- DEA number: none
U.S. Preparations:
- Serlect® (Abbott Laboratories) FDA approved: not approved
Preparations Outside U.S.:
- Serdolect
Stephen Stahl's Clinical Pearls* (Consult your physician before making any change in your treatment.)
- Prolongs QTc on EKG.
- Currently 'on hold' from marketing until relationship of QTc prolongation to ventricular arrhythmias and sudden deaths clarified.
- Before withdrawal from marketing, pre-treatment EKG was recommended.
- Contraindicated in patients with prolonged QT intervals, with significant cardiac disease, uncorrected hypokalemia, and concomitant use of other drugs that prolong the QT interval
- Accepted as efficacious for treatment of schizophrenia and bipolar disorders
- Anecdotal reports of use in children, and treatment-refractory cases, and for positive symptoms of psychosis in disorders other than schizophrenia
- May cause less weight gain than other antipsychotics.
- Never say never, but essentially no EPS at any dose.
- Can cause nasal congestion and decreased ejaculatory volume.
| Books and Other Media: Follow the hypertext link to purchase items online. |
|
*Reprinted with permission from: Stahl, Stephen M Psychopharmacology of Antipsychotics Paperback 1999 Martin Dunitz, Ltd You cannot fully appreciate this book until you have seen the extraordinary illustrations of every aspect of this area of psychopharmacology and neurochemistry. Loaded with practical clinical "pearls."